Skip to main content
OpenTrials
Completed

NCT Number: NCT04493554

The Effects of Vasopressin on Attention Control

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, 611731, China

About this study

A number of previous studies have reported vasopressin's effect on human social behavior and social cognition, although it remains unclear whether vasopressin could modulate attention allocation including stimulus-driven bottom-up control and goal-directed top-down control. In the current randomized, between-subject, placebo controlled study, 89 healthy male subjects will be recruited and receive either vasopressin (20 IU) or placebo control administered intranasally. 45 minutes after treatment subjects will be required to complete a social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of vasopressin.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy participants
  • Non smokers

Exclusion criteria

  • Previous or current medical, psychiatric, neurological disorder
  • Regular medication
  • Use of any psychoactive substances in the 24 hours before experiment
  • Contra-indications for vasopressin
  • Contra-indications for eye-tracking data acquisition

Treatment and study plan

Vasopressin

Drug

Administration of vasopressin (20 IU) intranasally

Placebo

Drug

Administration of placebo intranasally

Primary outcomes

  1. Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli

    Time frame: 45 minutes - 100 minutes after treatment

    Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions

  2. Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli

    Time frame: 45 minutes - 100 minutes after treatment

    Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions

Secondary outcomes

  1. Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions

    Time frame: 45 minutes - 100 minutes after treatment

    Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions

  2. Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions

    Time frame: 45 minutes - 100 minutes after treatment

    Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions

Sponsors and collaborators

Lead sponsor

University of Electronic Science and Technology of China

Other

Registry information

Official study title

The Effects of Vasopressin on Attention Control: An Eye-tracking Study

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Jul 30, 2020
Registry last updated
Jan 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.